Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Forrester

- PMLiVE

EU moves forward with legal action against AZ over vaccine supply issues

Legal proceeding launched on the basis of 'breaches of the advanced purchase agreement'

- PMLiVE

GSK wins approval for anti-PD-1 antibody Jemperli in endometrial cancer

AnaptysBio earns a $20m milestone payment on approval after originally developing the drug

- PMLiVE

EU may seek legal action against AstraZeneca following vaccine supply cuts

EU supply issues for the AZ vaccine started in January 2021

- PMLiVE

Valneva to compare its COVID-19 vaccine candidate to AstraZeneca’s jab

Phase 3 trial will test Valneva’s vaccine candidate against Vaxzevria in approximately 4,000 participants

Empowering patients empowers results

Patient-centricity is key when it comes to creating a more flexible, efficient and modern process for clinical trials

- PMLiVE

GSK discontinues two feladilimab trials in head and neck cancer

Decision made after recommendation from Independent Data Monitoring Committee

- PMLiVE

UPDATE: AZ/Oxford University COVID-19 vaccine gets EU approval

MHRA is looking "very closely" at reports of adverse reactions to coronavirus vaccines

- PMLiVE

AZ showcases data for next-generation PARP inhibitor AZD5305

Early preclinical data presented at virtual American Association of Cancer Research meeting

Virtually, the same: Is it time to rethink congress strategy?

In this month’s PME, Jonathan Andrew, Technology Director at Lucid Group discusses the digital transformation that swept through the medcomms industry due to the COVID-19 pandemic. In particular, we saw...

Lucid Group Communications Limited

Advancing the Scientific Understanding of Medical Cannabis Through Real-Time User Data

David Berg, President and CTO of Strainprint, explores the current state of the medical cannabis industry in Canada and overseas and how Strainprint is bringing innovation to the industry. He...

Impetus Digital

- PMLiVE

New restrictions for AZ/Oxford COVID-19 vaccine despite EMA endorsement

Regulators in Canada and Germany have reportedly placed new restrictions on vaccine

- PMLiVE

Pfizer/BioNTech’s COVID-19 vaccine is 100% effective in adolescents

Vaccine was found to be safe and effective in adolescents aged 12 to 15 years old

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links